Search
Griseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Vancomycin
go.drugbank.com/drugs/DB00512ApprovedInvestigationalIt is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. … As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis
Products: VANCOMICINA BONISCONTRO E GAZZONE, İNFÜZYONLUK VE ORAL ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ, 1 ADETMipomersen
go.drugbank.com/drugs/DB05528ApprovedIt is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. … Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Methyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedThe action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation. … Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.
Aspergillus flavus
go.drugbank.com/drugs/DB10694ApprovedAspergillus flavus is a fungus which can provoke allergic reactions. Aspergillus flavus extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigationalOne of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … alfa], to counter the decrease in endogenous EPO production.
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalIn the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Products: SIMPONI 50MG ILO I E FERAtacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigationalAtacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.